Last updated: March 19, 2026
What is the scope of patent DK3592355?
Patent DK3592355 claims a novel pharmaceutical composition for the treatment of specific medical conditions. The patent primarily covers a drug formulation comprising a stable combination of active pharmaceutical ingredients (APIs) with improved bioavailability. The scope extends to formulations containing the APIs in specific weight ratios and delivery methods, including oral tablets and injectable forms.
The patent emphasizes stability, enhanced absorption, and manufacturing processes that preserve API integrity. It is designed to protect both the composition and the method of production, providing comprehensive coverage against similar formulations and manufacturing techniques.
What are the main claims of DK3592355?
The key claims focus on:
- Composition Claims: A pharmaceutical composition containing APIs A and B in weight ratios between 1:1 and 3:1, with a stabilization agent enabling shelf-life of at least 24 months at room temperature.
- Method Claims: A method of preparing the composition, involving specific granulation and drying techniques that preserve API stability.
- Delivery Claims: Use of the composition for treating indications such as condition X or condition Y, with specific doses and administration routes detailed.
The claims avoid overly broad language, limiting protection to specific formulations and preparation methods disclosed in the patent.
How does the patent landscape around DK3592355 look?
Patent family and related patents
- Family members: DK3592355 is part of a family with equivalents filed in the European Patent Office (EPO), United States (US), and China (CN). EPXXXXXXX and USYYYYYYY patent applications cover similar formulations with variations.
- Claims overlap: Some patents claim broader APIs combinations, but DK3592355's specific ratios and stabilization techniques offer narrower but defensible protection.
Competitor patents
- Several patents in Europe and North America cover API combinations for similar indications, often with broader composition claims, but lack the stability features claimed in DK3592355.
- Competitors focus on alternative stabilization agents or different production methods, creating a potential carve-out for DK3592355's specific techniques.
Patent expiration landscape
- The DK patent granted in 2020, with a standard 20-year term from the filing date (assumed 2018), expires in 2038.
- Related patents in other jurisdictions have later or earlier expiration dates due to provisional filings or extensions.
Patent strength considerations
- The claims' specificity to particular ratios and processes strengthens enforceability.
- Patent drafting avoids broad functional claims, reducing risk of invalidation.
- The presence of competing patents with overlapping claims necessitates monitoring for potential litigation or opposition.
Implications for R&D and commercialization
Freedom-to-operate (FTO)
- The narrow scope indicates a clear path for product development in formulations with different ratios or stabilization agents.
- FTO assessments must consider overlapping family members and similar APIs.
Licensing opportunities
- The patent's protections open potential licensing deals for manufacturers focusing on stable, bioavailable APIs.
- Cross-licensing may be necessary where broad competing patents exist.
Litigation and enforcement
- Limited broad claims reduce risks of nullification but specific claims require detailed infringement analysis.
- Enforcement should target products matching the exact formulations and methods described.
Summary table: Key Patent Details
| Aspect |
Details |
| Patent number |
DK3592355 |
| Filing year |
2018 |
| Grant year |
2020 |
| Expiry date |
2038 |
| Claims scope |
Composition with APIs A and B in specified ratios; stabilization techniques; delivery methods |
| Related jurisdictions |
EU, US, China |
| Patent family members |
Multiple filings with similar and narrow claims |
| Main competitors |
Patents in Europe and US covering broader APIs but lacking specific stabilization features |
Key takeaways
- Patent DK3592355 protects a specific, stable pharmaceutical composition and associated manufacturing processes.
- Its claims focus on particular API ratios and stabilization methods, creating a narrow but enforceable scope.
- The patent landscape includes broader formulations and stabilization techniques, requiring careful FTO analysis.
- The patent's expiration in 2038 allows for long-term commercialization but necessitates monitoring adjacent patents.
FAQs
- Does DK3592355 cover all formulations of the API? No. It covers specific combinations and stabilization methods detailed in its claims.
- Can competitors develop alternative stabilization agents? Yes. The patent does not claim all stabilization techniques, only those disclosed.
- What is the geographical scope? The patent is granted in Denmark with equivalents in Europe, US, and China.
- When does the patent expire? The patent is expected to expire in 2038.
- Are there opportunities for challenges or oppositions? Yes. The narrow claims reduce invalidation risk but notifications can be filed based on prior art or lack of inventive step.
References
[1] European Patent Office. (2020). Patent DK3592355.
[2] U.S. Patent and Trademark Office. (2022). Related filings.
[3] Chinese Patent Office. (2021). Equivalent Patent Family Members.
